483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers

MLA

Jeffrey Schlom, et al. “483 Initial Safety Results and Immune Responses Induced by a Novel Human Papillomavirus (HPV)-Specific Gorilla Adenovirus Immunotherapy Vaccine, PRGN-2009, in Patients with Advanced HPV-Associated Cancers.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, Nov. 2021. EBSCOhost, https://doi.org/10.1136/jitc-2021-SITC2021.483.

APA

Jeffrey Schlom, Ravi Madan, Seth Steinberg, James Gulley, Caroline Jochems, Renee Donahue, Sheri McMahon, Lisa Cordes, Julius Strauss, Fatima Karzai, Jason Redman, Charalampos Floudas, Clint Allen, Douglas Brough, Amy Lankford, & Jenn Marte. (2021). 483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers. Journal for ImmunoTherapy of Cancer, 9(Suppl 2). https://doi.org/10.1136/jitc-2021-SITC2021.483

Chicago

Jeffrey Schlom, Ravi Madan, Seth Steinberg, James Gulley, Caroline Jochems, Renee Donahue, Sheri McMahon, et al. 2021. “483 Initial Safety Results and Immune Responses Induced by a Novel Human Papillomavirus (HPV)-Specific Gorilla Adenovirus Immunotherapy Vaccine, PRGN-2009, in Patients with Advanced HPV-Associated Cancers.” Journal for ImmunoTherapy of Cancer 9 (Suppl 2). doi:10.1136/jitc-2021-SITC2021.483.